Moreover, the activity of glutamine synthetase that converts glutamate to glutamine, in the cerebrospinal fluid was also found to be increased not only in AD patients but also VaD and ALS, further indicating that the glutamate/glutamine cycle is compromised in neurodegenerative conditions and that alteration of blood glutamate may be beneficial in treating these toxic episodes [55, 56]. The gene discussed is GLUL; the disease is Alzheimer disease.